Hypothesis: The potential therapeutic role of nicorandil in COVID-19.
Clin Exp Pharmacol Physiol
; 47(11): 1791-1797, 2020 11.
Article
in English
| MEDLINE | ID: covidwho-695227
ABSTRACT
At present, there is yet no specific antiviral treatment or immunization against the newly identified human severe acute respiratory syndrome virus (SARS-CoV2) that results in a rapidly progressive pandemic coronavirus disease 2019 (COVID-19). We believe in a crucial need for a clinical strategy to counteract this viral pandemic based on the known pathogenesis throughout the disease course. Evidence suggests that exaggerated patient's inflammatory response and oxidative stress are likely to aggravate the disease pathology. The resulting endothelial dysfunction further induces fibrosis and coagulopathy. These disturbances can generate severe acute respiratory distress syndrome (ARDS) that can progress into respiratory and circulatory failure. Nicorandil is an anti-anginal vasodilator drug acts by increasing nitric oxide bioavailability and opening of the KATP channel. Recently, nicorandil has been recognized to possess multiple protective effects against tissue injury. Here, we address a possible modulatory role of nicorandil against COVID-19 pathogenesis. We hypothesise nicorandil would be an effective form of adjuvant therapy against COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Vasodilator Agents
/
Coronavirus Infections
/
Nicorandil
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Clin Exp Pharmacol Physiol
Year:
2020
Document Type:
Article
Affiliation country:
1440-1681.13395
Similar
MEDLINE
...
LILACS
LIS